1,275 reports of this reaction
2.0% of all NICOTINE POLACRILEX reports
#7 most reported adverse reaction
HEADACHE is the #7 most commonly reported adverse reaction for NICOTINE POLACRILEX, manufactured by Haleon US Holdings LLC. There are 1,275 FDA adverse event reports linking NICOTINE POLACRILEX to HEADACHE. This represents approximately 2.0% of all 62,946 adverse event reports for this drug.
NICOTINE POLACRILEX has an overall safety score of 78 out of 100. Patients taking NICOTINE POLACRILEX who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for NICOTINE POLACRILEX, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for NICOTINE POLACRILEX:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 1,275 FDA reports for NICOTINE POLACRILEX. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.0% of all adverse event reports for NICOTINE POLACRILEX, making it a notable side effect.
If you experience headache while taking NICOTINE POLACRILEX, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.